Skip to content

Development of Intelligent Urodynamic Diagnosis Model

Development of Intelligent Urodynamic Diagnosis Model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063467
Enrollment
Unknown
Registered
2022-09-07
Start date
2022-09-07
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary dysfunction related diseases

Interventions

Overactive bladder group:NA
Lower urinary tract obstruction group:NA
Neurogenic bladder group:NA

Sponsors

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 75 Years

Inclusion criteria

Inclusion criteria: Control group: Normal control group whose urine storage and urination function was normal, and no abnormal signal was found in the urodynamic map. Experimental group 1: Overactive bladder group who performs frequent uninhibited bladder contractions during urine storage periop. Involuntary detrusor pressure can be seen in the detrusor pressure curve in the urodynamic map. Test group 2: Lower urinary tract obstruction group whose bladder pressure was significantly increased during urination. Meanwhile, the urine flow rate was low and flat, with or without lower urinary tract obstructive disease. Test group 3: Neurogenic bladder group that exist bladder compliance changes, detrusor hyperactivity or weakness. In addition, abdominal pressure assisting urination, and abnormal urine flow curve can be seen in urination period.

Exclusion criteria

Exclusion criteria: 1. T-doc pressure measuring tube cannot be placed due to urethrostenosis; 2. Acute urinary tract infection; 3. Coagulation dysfunction; 4. Patients with severe medical complications have high operational risk so that cannot tolerate urodynamic testing, such as severe pulmonary dysfunction, severe cardiovascular disease, active infectious disease, immunodeficiency disease, or taking hormones or immunosuppressants.

Design outcomes

Primary

MeasureTime frame
Urodynamic map;

Countries

China

Contacts

Public ContactZhong Chen

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

chenzhongtj@126.com+86 13607150950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 1, 2026